Biocartis introduces CE-IVD marked Idylla KRAS mutation test

Biocartis, an innovative molecular diagnostics company, announced the launch of its CE-IVD marked Idylla KRAS mutation test, a sample-to-result test for the fast, accurate and reproducible detection of 21 relevant mutations in the KRAS oncogene.Biocartis

The Idylla KRAS mutation test is the first fully-automated CE-IVD test available for routine use that detects all clinically relevant driver mutations of the KRAS oncogene in tissue of colorectal cancers (CRC) at a sensitivity of 5 per cent as recommended according to ESMO, NCCN, and the recently issued CAP/AMP/ASCO guidelines. Unique to the Idylla KRAS mutation test is its ability to detect all relevant mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61) and exon 4 (codons 117 and 146) of the KRAS gene.

Validation studies and pre-market trials on more than 500 mCRC patient samples have demonstrated the excellent accuracy of the Idylla KRAS mutation test. During the validation study, the Idylla KRAS mutation test detected 8 per cent more mutations than the reference test. Between-lab reproducibility studies showed a 100 per cent agreement between all participating sites, demonstrating that the Idylla KRAS mutation test is easy to implement and highly standardized.

The Idylla KRAS mutation test runs on the Idylla platform and provides accurate and actionable results in an unprecedented timeframe of approximately two hours. Hands-on time is less than two minutes as the formalin-fixed, paraffin embedded (FFPE) tissue is directly inserted into the Idylla cartridge without any prior deparaffinization or other pre-processing steps.

Dr. Alberto Bardelli, director of the Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, Torino, Italy, commented “Biocartis has crafted an innovative KRAS test that offers exactly what is currently needed in the field. The Idylla KRAS mutation test has an excellent sensitivity and detects 21 mutations in all of the relevant codons of KRAS exons 2, 3 and 4. These unique features, combined with ease of use and short turnaround time, are expected to be of benefit to any lab.”

The Idylla KRAS mutation test is the second test launched by Biocartis and a cornerstone in a set of highly standardized and sensitive tests around metastatic colorectal cancer. A similar extended NRAS panel, which can be combined with KRAS for the detection on an extended panel of 40 RAS mutations in combination with BRAF and EGFR492 mutations, is currently in development.

Idylla, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime. The Idylla platform covers the entire process from sample to result in a time frame of 35 to 150 minutes with less than two minutes hands-on time. Idylla is applicable for a wide range of clinical sample types and can analyze both RNA and DNA. The fully integrated system enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond. Idylla and the system’s first assays, the Idylla BRAF mutation test for metastatic melanoma and Idylla KRAS mutation test have obtained CE-IVD marking.

KRAS is a protein which plays a role in cell proliferation, angiogenesis, migration, cell survival and cell adhesion. When KRAS is mutated, it leads to uncontrolled cell growth and division that may result in cancer. Biocartis estimates that around 45 per cent of patients in Europe with colorectal cancer, roughly 100,000 people, are eligible for KRAS testing.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top